Uygun-Kiehne S, Straube R, Heibges A, Klingel R, Davids H
HNO-Klinik, Klinikum Lüdenscheid, Lüdenscheid, Deutschland.
HNO. 2010 May;58(5):445-51. doi: 10.1007/s00106-009-2004-2.
For patients suffering from recurrent sudden hearing loss (SHL) that is refractory to infusion therapy, new therapeutic options must be established.
Patients suffering from recurrent and progressive SHL refractory to infusion therapy according to German guidelines were analysed retrospectively. After unsuccessful infusion therapy following the last onset of SHL, patients were treated with Rheopheresis twice. Hearing gain and recovery of speech discrimination were analysed.
Twenty-five patients with a mean of 2.1+/-0.4 events of SHL within 30.0+/-21.6 months were examined. The patients' mean hearing loss before the first onset of SHL was 34 dB and was reduced by infusion therapy to 20 dB. With the second onset of SHL, hearing loss remained almost unchanged after infusion therapy. Patients showed a mean improvement of 20 dB after two consecutive Rheopheresis treatments. Forty percent showed complete remission of SHL, and a further 28% showed partial remission.
Rheopheresis can efficiently improve the hearing of patients with recurrent SHL refractory to infusion therapy.
对于患有复发性突发性听力损失（SHL）且对输液治疗无效的患者，必须确立新的治疗选择。
回顾性分析了根据德国指南对输液治疗无效的复发性、进行性SHL患者。在最后一次SHL发作后输液治疗失败后，患者接受了两次血液成分单采治疗。分析听力增益和言语辨别力的恢复情况。
检查了25例患者，平均在30.0±21.6个月内发生2.1±0.4次SHL事件。患者首次发生SHL前的平均听力损失为34dB，经输液治疗后降至20dB。第二次发生SHL时，输液治疗后听力损失几乎没有变化。患者在连续两次血液成分单采治疗后平均改善了20dB。40%的患者SHL完全缓解，另有28%的患者部分缓解。
血液成分单采可有效改善对输液治疗无效的复发性SHL患者的听力。
